A four‐group urine risk classifier for predicting outcomes in patients with prostate cancer.

Really pleased to announce the publication of our latest bit of research

https://doi.org/10.1111/bju.14811


We have developed a urine test to diagnose aggressive prostate cancer and predict whether patients will require treatment up to five years earlier than standard clinical methods. The experimental new test called ‘PUR’ (Prostate Urine Risk) also identifies men who are up to eight times less likely to need treatment within five years of diagnosis. It is hoped that the breakthrough could help large numbers of men avoid an unnecessary initial biopsy and repeated invasive follow-ups for ‘low risk’ patients on active surveillance.

This work was funded by the Movember Foundation, The Masonic Charitable Foundation, The Bob Champion Cancer Trust, the King family, the Andy Ripley Memorial Fund and the Stephen Hargrave Trust.

We've had quite a bit of press attention:

Comments

Popular posts from this blog

A census of amplified and overexpressed human cancer genes : Nature Reviews Cancer

RT @CancerInNorwich: 📢 Join us on Monday at 1pm for the next talk in our virtual seminar series. We will be hearing from Dr Wafa Al-Jamal from @QUBelfast, who will be talking about "Smart Nanomedicimes for Pancreatic Cancer". All are welcome to join via the MS Teams link: https://t.co/4xCYpjGuBZ https://t.co/EGyD4NAgeP

An excellent opportunity to join the cancer genetics team as a diagnostic lab bioinformatician in Norwich. Lots of exciting projects to get involved in. Deadline: 30/05/2023. Happy to chat about this role. https://t.co/SltGsxYF6Y https://t.co/zh08bqZFDb